BOSTON– Zealand Pharma A/S, a biotechnology company focused on the design and development of innovative peptide-based medicines, is expanding its U.S. headquarters in Boston’s Seaport District.
Zealand will occupy 10,600 square feet at 44 Farnsworth Street within Nuveen’s Fort Point Channel office portfolio. This expansion comes after receiving approval from the U.S. Food and Drug Administration (FDA) for Zegalogue® (dasiglucagon) injection, a treatment for severe hypoglycemia in people with diabetes above the age of six.
Bobby Jangro and Tucker Hansen of JLL represented the tenant, Zealand Pharma, in the company’s site selection and lease negotiation of the new office space. Dan Cavanaugh and Patrick Nugent of JLL represented the landlord, Nuveen.
“We spent a lot of time thinking strategically about location and proximity to partners, peer companies and other industry leaders,” said Bobby Jangro, Executive Vice President at JLL and part of the team representing Zealand Pharma. “Zealand’s expansion in Seaport is a testament to the strength of the Seaport District’s life sciences cluster.”